You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy

 

Online download statistics by month:

Online download statistics by month: July 2020 to September 2024

AbstractFullPdf
Jul 2020359359124
Aug 2020251250119
Sep 202016116180
Oct 202011011077
Nov 2020929234
Dec 202020720735
Jan 202119019065
Feb 202120620674
Mar 202119519574
Apr 202116316342
May 202113813840
Jun 202111211245
Jul 202112612651
Aug 202110310347
Sep 202111711750
Oct 2021646454
Nov 2021585837
Dec 2021333421
Jan 202214816070
Feb 2022727534
Mar 202210311059
Apr 2022819737
May 2022828982
Jun 2022879261
Jul 2022778258
Aug 2022748037
Sep 20228387112
Oct 202210911756
Nov 2022878843
Dec 2022616361
Jan 2023949633
Feb 202310610637
Mar 2023929332
Apr 2023767932
May 2023828339
Jun 2023656519
Jul 2023474930
Aug 2023525217
Sep 2023595926
Oct 2023666721
Nov 202312212427
Dec 202322422416
Jan 2024434627
Feb 202413413425
Mar 2024989936
Apr 2024667033
May 2024646430
Jun 2024555634
Jul 2024707635
Aug 2024474985
Sep 202448481699
Total545955644112